Comparative Pharmacology
Head-to-head clinical analysis: DASETTA 1 35 versus JAIMIESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DASETTA 1 35 versus JAIMIESS.
DASETTA 1/35 vs JAIMIESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone). Suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus (impenetrability to sperm) and endometrium (reduced likelihood of implantation).
Norepinephrine and dopamine reuptake inhibitor; also weakly inhibits serotonin reuptake. Enhances synaptic concentrations of norepinephrine and dopamine, particularly in prefrontal cortex.
One tablet orally once daily, each containing 1 mg norethindrone acetate and 35 mcg ethinyl estradiol.
100 mg orally once daily with food.
None Documented
None Documented
Norethindrone: 5-14 hours (mean 8 hours); ethinyl estradiol: 10-20 hours (mean 14 hours). Clinical context: steady-state achieved within 5-7 days.
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in severe impairment).
Renal (55-60% as metabolites, 25-30% as unchanged drug and conjugates), biliary/fecal (30-35% as metabolites).
Primarily renal excretion as unchanged drug (approximately 70%) with the remainder as inactive metabolites; less than 10% excreted in feces.
Category C
Category C
Oral Contraceptive
Oral Contraceptive, Combined